Dual-listed Tiziana Life Sciences (NASDAQ:TLSA) has climbed ~45.4% today as the company prepares to delist from AIM and start trading on the main market for listed securities of London Stock Exchange.

双重上市公司Tiziana生命科学公司(NASDAQ:TLSA)股价上涨45.4%，该公司准备从AIM摘牌，开始在伦敦证券交易所上市交易。

The last day of trading of the Company's Ordinary Shares on AIM is January 20 and admission of shares to the Official List and commencement of dealing on the Main Market will be effective from 8.00 am on January 21. Tiziana shares have nearly tripled over the past twelve-month period.

本公司普通股在AIM的最后交易日为1月20日，股票进入正式上市及在主要市场开始交易将于1月21日上午8时起生效。在过去的12个月里，Tiziana的股价几乎涨了两倍。

Early this month, the shares added 27.7% after the company announced the completion of a clinical study conducted in Brazil that investigated nasally administered Foralumab with or without orally administered dexamethasone in COVID-19 patients. The top-line results from the trial are expected this month.

本月初，该公司宣布完成了在巴西进行的一项临床研究，该研究对COVID-19患者鼻用或不口服地塞米松给予福鲁单抗进行了调查，随后股价上涨了27.7%。该试验的最高结果预计将于本月公布。